Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KYNU | Q16719 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21405660 | 0.83 | LMNA (0.40) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL372487 | 0.83 | LMNA (0.40) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL31357901 | 0.83 | LMNA (0.40) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL29154198 | 0.79 | ALDH1A1 (0.43) | AKR1C3AKR1C2POLBHTR1AADRA1A | |
| SCHEMBL262673 | 0.76 | HTT (0.45) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL5696122 | 0.71 | LMNA (0.39) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL9098490 | 0.71 | BCHE (0.49) | AKR1C3AKR1C2AKR1C1PTGS1HSD17B10 | |
| SCHEMBL28563997 | 0.71 | MEN1 (0.46) | AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL10580121 | 0.70 | LMNA (0.41) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL6773227 | 0.70 | TSHR (0.57) | AKR1C3AKR1C2AKR1C1PTGS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007059569-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2007-05-31 | — | — | WO | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032417-A1 | Peptides and therapeutic uses thereof | BCL2, BAX, BCL2L13 | CPN1 929/4885CPB2 253/4885AKR1C3 4565/4885 |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | BCL2, BAX, BAD | CPN1 1550/4885CPB2 451/4885AKR1C3 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.